ArticleAging2021

Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.

Yuan Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.